Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New trends in antimicrobial development.

E L Setti1, R G Micetich

  • 1Axys Pharmaceuticals, Inc., South San Francisco, California 94080, USA.

EXS
|September 21, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

(1)H-NMR and NOE studies of 2-cephems and 3-cephems.

Archives of pharmacal research·2008
Same author

Monobactams as enzyme inhibitors.

IDrugs : the investigational drugs journal·2005
Same author

4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives as anti-tumor agents.

Current medicinal chemistry. Anti-cancer agents·2003
Same author

In vitro and in vivo activities of syn2836, syn2869, syn2903, and syn2921: new series of triazole antifungal agents.

Antimicrobial agents and chemotherapy·2001
Same author

Practical aspects of liquid chromatography/electrospray tandem mass spectrometry for rapid identification of metabolites of a new antifungal agent SYN-2836 in dog urine.

Rapid communications in mass spectrometry : RCM·2001
Same author

High-performance liquid chromatographic assay for the determination of novel triazole antifungal agents in tissue. Application to tissue distribution studies.

Biomedical chromatography : BMC·2000
Same journal

Forensic toxicology.

EXS·2010
Same journal

Biological warfare agents.

EXS·2010
Same journal

Chemical warfare agents.

EXS·2010
Same journal

Drugs of abuse: management of intoxication and antidotes.

EXS·2010
Same journal

Biological testing for drugs of abuse.

EXS·2010
Same journal

Inhalation toxicology.

EXS·2010
See all related articles

Developing new anti-infective agents involves creating antibiotic analogs and screening compounds. Current research focuses on novel targets, including resistance and virulence factors, driven by advances in understanding infection mechanisms.

Area of Science:

  • Microbiology
  • Drug Discovery
  • Molecular Biology

Background:

  • Traditional anti-infective development relies on synthesizing antibiotic analogs and screening compounds.
  • Emerging infectious diseases and antimicrobial resistance necessitate novel therapeutic strategies.

Purpose of the Study:

  • To explore the evolving strategies for developing new anti-infective agents.
  • To highlight the shift towards targeting specific resistance and virulence factors.

Main Methods:

  • Synthesis of classical antibiotic analogs.
  • Screening of natural and synthetic compound libraries.
  • Investigating novel molecular targets based on cell biology and pathogenicity.

Main Results:

Related Experiment Videos

  • Classical strategies remain relevant but are being augmented.
  • A deeper understanding of bacterial resistance and infection mechanisms is driving target discovery.

Conclusions:

  • Novel anti-infective agents are increasingly discovered by targeting specific bacterial factors.
  • Advances in understanding cell biology and pathogenicity are crucial for identifying new therapeutic targets.